207 related articles for article (PubMed ID: 31703602)
1. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Ihle CL; Provera MD; Straign DM; Smith EE; Edgerton SM; Van Bokhoven A; Lucia MS; Owens P
J Immunother Cancer; 2019 Nov; 7(1):293. PubMed ID: 31703602
[TBL] [Abstract][Full Text] [Related]
2. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
Straign DM; Ihle CL; Provera MD; Owens P
Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
[TBL] [Abstract][Full Text] [Related]
3. Integrating the immune microenvironment of prostate cancer induced bone disease.
Ihle CL; Owens P
Mol Carcinog; 2020 Jul; 59(7):822-829. PubMed ID: 32233011
[TBL] [Abstract][Full Text] [Related]
4. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
Al Nakouzi N; Bawa O; Le Pape A; Lerondel S; Gaudin C; Opolon P; Gonin P; Fizazi K; Chauchereau A
Neoplasia; 2012 May; 14(5):376-87. PubMed ID: 22745584
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.
Virk MS; Alaee F; Petrigliano FA; Sugiyama O; Chatziioannou AF; Stout D; Dougall WC; Lieberman JR
Bone; 2011 Mar; 48(3):578-87. PubMed ID: 21073986
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
7. The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
Iglesias-Gato D; Thysell E; Tyanova S; Crnalic S; Santos A; Lima TS; Geiger T; Cox J; Widmark A; Bergh A; Mann M; Flores-Morales A; Wikström P
Clin Cancer Res; 2018 Nov; 24(21):5433-5444. PubMed ID: 30042207
[No Abstract] [Full Text] [Related]
8. Bone morphogenetic protein pathway responses and alterations of osteogenesis in metastatic prostate cancers.
Provera MD; Straign DM; Karimpour P; Ihle CL; Owens P
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1707. PubMed ID: 36054271
[TBL] [Abstract][Full Text] [Related]
9. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.
Akfirat C; Zhang X; Ventura A; Berel D; Colangelo ME; Miranti CK; Krajewska M; Reed JC; Higano CS; True LD; Vessella RL; Morrissey C; Knudsen BS
J Pathol; 2013 Jul; 230(3):291-7. PubMed ID: 23420560
[TBL] [Abstract][Full Text] [Related]
10. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
Eaton CL; Colombel M; van der Pluijm G; Cecchini M; Wetterwald A; Lippitt J; Rehman I; Hamdy F; Thalman G
Prostate; 2010 Jun; 70(8):875-82. PubMed ID: 20127735
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
Schwartz GG
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):478-83. PubMed ID: 18349265
[TBL] [Abstract][Full Text] [Related]
15. Conventional finite element models estimate the strength of metastatic human vertebrae despite alterations of the bone's tissue and structure.
Stadelmann MA; Schenk DE; Maquer G; Lenherr C; Buck FM; Bosshardt DD; Hoppe S; Theumann N; Alkalay RN; Zysset PK
Bone; 2020 Dec; 141():115598. PubMed ID: 32829037
[TBL] [Abstract][Full Text] [Related]
16. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
18. FGF-8 is involved in bone metastasis of prostate cancer.
Valta MP; Tuomela J; Bjartell A; Valve E; Väänänen HK; Härkönen P
Int J Cancer; 2008 Jul; 123(1):22-31. PubMed ID: 18386787
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner.
Henrich SE; McMahon KM; Plebanek MP; Calvert AE; Feliciano TJ; Parrish S; Tavora F; Mega A; De Souza A; Carneiro BA; Thaxton CS
J Extracell Vesicles; 2020 Dec; 10(2):e12042. PubMed ID: 33408816
[TBL] [Abstract][Full Text] [Related]
20. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
